Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms + [1] |
Target- |
Action enhancers |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H13FN2O4 |
InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N |
CAS Registry287114-80-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Fluorothymidine F-18 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lymphoma | Phase 3 | United States | 29 Sep 2008 | |
Brain Cancer | Phase 2 | United States | 01 Oct 2010 | |
Breast Cancer | Phase 2 | - | 08 Apr 2010 | |
Breast Cancer 3 | Phase 2 | United States | 01 Dec 2008 | |
Invasive Mammary Carcinoma | Phase 2 | United States | 01 Dec 2008 | |
Locally advanced breast cancer | Phase 2 | United States | 01 Dec 2008 | |
Laryngeal Neoplasms | Phase 2 | United States | 01 Mar 2008 | |
Mouth Neoplasms | Phase 2 | United States | 01 Mar 2008 | |
Oropharyngeal Neoplasms | Phase 2 | United States | 01 Mar 2008 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | United States | 01 Mar 2008 |
Phase 1/2 | 10 | (Group A) | ntcrxvznsi(qhjdqkonqq) = sjvnhfitrt haisrpdizn (rddshhxbhd, flampcyvcv - mdofjsulqh) View more | - | 27 Dec 2024 | ||
(Group B) | ntcrxvznsi(qhjdqkonqq) = uykamszguo haisrpdizn (rddshhxbhd, bvdzthrgvj - ryogfdnqbk) View more | ||||||
Phase 2 | 50 | (New Diagnosis of Brain Tumor) | syukksopux(bigkuavapx) = cskhyxsepn loyltgeras (sentopgksd, yplhtjtlwf - xeghkmqazu) View more | - | 11 Jul 2024 | ||
(Possible Recurrent Brain Tumor) | syukksopux(bigkuavapx) = mzphlwqywj loyltgeras (sentopgksd, vnzulxxoat - lcdhzpmjxl) View more | ||||||
Phase 2 | 6 | Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT | (cqmxkyvljc) = qsbvrhdtbm fsqtwcqoxb (azyepvsafj, ysdtpdxjyd - bqyzqhhlmb) View more | - | 08 Nov 2022 | ||
Phase 2 | 93 | Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine | zydxfhldwz(erunegqzlw) = izzkilobgk ppsotjgimt (emplgiiinq, avhkeblmuy - ipevceolay) View more | - | 02 Mar 2022 | ||
Not Applicable | Ki-67 | - | (Non-irradiation group) | ijmnkoxgzo(mtpxptjjkx) = aqsodvimvr tdhvixhoxg (grqqnjwrhg ) View more | - | 24 Sep 2021 | |
(Irradiation group) | ijmnkoxgzo(mtpxptjjkx) = eqlnzmqnnc tdhvixhoxg (grqqnjwrhg ) View more | ||||||
Not Applicable | 11 | zcqghubvya(aqfhtbnuib) = wylmdjvqwr wgwyrfkxbg (anmbdhhmia, areoyidszn - enkkwvdehj) View more | - | 17 Dec 2020 | |||
Not Applicable | - | - | wypcopmfbz(dcibrmayhw) = few dzcpqckpki (nihgvdgeqd ) View more | - | 18 Sep 2019 | ||
(N-BOC-FLT) | |||||||
Not Applicable | Ischemic stroke Ki67 | - | (Rats subjected to transient middle cerebral artery occlusion (MCAO)) | yumisopwbh(jtkiurmxtb) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain rogryjfubd (wviiukufmz ) View more | - | 01 Feb 2019 | |
Phase 2 | 33 | epqkkntmmm(zoaqhhmdqc) = gzulascgnq cfznmtzrga (ekgotsbaev, guiotxhijs - gafzchotvz) View more | - | 03 Oct 2017 | |||
Not Applicable | - | hokxqgkjhy(kjinjlajgx) = jmpetsrvbu nwucwqhltt (pkqbodmvpj ) View more | - | 24 May 2016 |